CYP2C9 polymorphisms in human tumors

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 299-305

  Knüpfer, Heike ^a   Stanitz, Dirk ^b   Preiss, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Hosp of the Paul Gerhardt Stiftung   (Germany)

Author keywords

Allele; CYP2C9; Polymorphism; RFLP

Indexed keywords

ALKYLATING AGENT; ARGININE; ASPARTIC ACID; CYCLOPHOSPHAMIDE; CYSTEINE; CYTOCHROME P450 2C9; GLYCINE; IFOSFAMIDE; ISOLEUCINE; LEUCINE; TYROSINE;

ARTICLE; BRAIN TUMOR; BREAST TUMOR; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG METABOLISM; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GLIOMA; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; EXONS; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 32144444918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Sladek NE: Metabolism of oxazaphosphorines. Pharmacol Ther 37: 301-355, 1988.
2. Chang TK, Weber GF, Crespi CL and Waxman DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629-5637, 1993.
3. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH and Idle JR: Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47: 1157-1163, 1994.
4. Walker D, Raun HK, Pearson ADJ and Idle JR: Cytochrome P450 3A5 (CYP3A5) makes a significant contribution to the metabolism in vitro of cyclophosphamide and ifosfamide. Proc Am Assoc Cancer Res 36: 2224, 1995.
5. Preiss R, Schmidt R, Baumann F, Hanschmann H, Hauss J, Geissler F, Pahlig H and Ratzewiss B: Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol 128: 385-392, 2002.
6. Chang TK, Yu L, Goldstein JA and Waxman DJ: Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 7: 211-221, 1997.
7. Gray IC, Nobile C, Muresu R, Ford S and Spurr NK: A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 28: 328-332, 1995.
8. Goldstein JA and de Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
9. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423, 1994.
10. Krishna DR and Klotz U: Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26: 144-160, 1994.
11. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, et al: Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 182: 1333-1339, 1990.
12. Kivisto KT, Fritz P, Linder A, Friedel G, Beaune P and Kroemer HK: Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochem Cell Biol 103: 25-29, 1995.
13. Kivisto KT, Linder A, Friedel G, Beaune P, Belloc C, Kroemer HK and Fritz P: Immunohistochemical localization of cytochrome P450 2E1 in human pulmonary carcinoma and normal bronchial tissue. Virchows Arch 426: 243-247, 1995.
14. Massaad L, de Waziers I, Ribrag V, Janot F, Beaune PH, Morizet J, Gouyette A and Chabot GG: Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res 52: 6567-6575, 1992.
15. Fritz P, Behrle E, Beaune P, Eichelbaum M and Kroemer HK: Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical characterization of cytochrome P4503A and glutathione-S-transferase. Histochemistry 99: 443-451, 1993.
16. Murray GI, Weaver RJ, Paterson PJ, Ewen SW, Melvin WT and Burke MD: Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol 169: 347-353, 1993.
17. Hellmold H, Rylander T, Magnusson M, Reiher E, Warner M and Gustafsson JA: Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasies. J Clin Endocrinol Metabol 843: 886-895, 1998.
18. Knüpfer H, Knüpfer MM, Hotfilder M and Preiß R: P450-expression in brain tumors. Oncol Res 11: 523-528, 1999.
19. Knüpfer H, Schmidt R, Stanitz D, Brauckhoff M, Schönfelder M and Preiss R: CYP2C and IL-6 expression in breast cancer. The Breast 13: 28-34, 2004.
20. Schmidt R, Baumann F, Knüpfer H, Brauckhoff M, Horn LC, Schönfelder M, Köhler U and Preiss R: CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br J Cancer 90: 911-916, 2004.
21. Xie HG, Prasad HC, Kim RB and Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54: 1257-1270, 2002.
22. Aoyama T, Korzekwa K, Nagata K, Adesnik M, Reiss A, Lapenson DP, Gillette J, Gelboin HV, Waxman DJ and Gonzalez FJ: Sequence requirements for cytochrome P-450IIB1 catalytic activity. Alteration of the stereospecificity and regioselectivity of steroid hydroxylation by a simultaneous change of two hydrophobic amino acid residues to phenylalanine. J Biol Chem 264: 21327-21333, 1989.
23. Lindberg RL and Negishi M: Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature 339: 632-634, 1989.
24. Faletto MB, Linko P and Goldstein JA: A single amino acid mutation (Ser180-Cys) determines the polymorphism in cytochrome P450g (P4502C13) by altering protein stability. J Biol Chem 267: 2032-2037, 1992.
25. Halpert JR and He YA: Engineering of cytochrome P450 2B1 specificity. Conversion of an androgen 16 beta-hydroxylase to a 15 alpha-hydroxylase. J Biol Chem 268: 4453-4457, 1993.
26. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ and Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349, 1996.
27. Bilzer T, Stavrou D, Dahme E, Keiditsch E, Burrig KF, Anzil AP and Wechsler W: Morphological, immunocytochemical and growth characteristics of three human glioblastomas established in vitro. Virchows Arch A Pathol Anat Histopathol 418: 281-293, 1991.
28. Stavrou D, Freiberg B, Meyermann R, Anzil AP, Keiditsch E and Mehraein P: Radioimmunodetection of human glioma xenografts by radiolabelled monoclonal antibodies. Anticancer Res 11: 537-542, 1991.
29. Wang SL, Huang J, Lai MD and Tsai JJ: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5: 37-42, 1995.
30. London SJ, Sullivan-Klose T, Daly AK and Idle JR: Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 7: 401-404, 1997.
31. Garcia-Martin E, Martinez C, Ladero JM, Gamito FJ, Rodriguez-Lescure A and Agundez JA: Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Lett 180: 41-46, 2002.
32. Martinez C, Garcia-Martin E, Ladero JM, Sastre J, Garcia-Gamito F, Diaz-Rubio M and Agundez JA: Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 22: 1323-1326, 2001.
33. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, Forman D, Bishop DT and Wolf CR; Colorectal Cancer Study Group: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23: 1839-1849, 2002.
34. Daly AK: Molecular basis of polymorphic drug metabolism. J Mol Med 75: 539-553, 1995.
35. Stubbins MJ, Harries LW, Smith G, Tarbit MH and Wolf CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6: 429-439, 1996.
36. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M and Sjoqvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254: 628-631, 1999.
37. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF and Rettie AE: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7: 361-367, 1997.
38. Burian M, Grösch S, Tegeder I and Geisslinger G: Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 54: 518-521, 2002.
39. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E and Ingelmann-Sundberg M: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and black African population. Br J Clin Pharmacol 52: 447-450, 2001.
40. Gotoh O: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267: 83-90, 1992.
41. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T: Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7: 103-113, 1997.
42. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP and Shimada T: Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56: 243-251, 1998.
43. Yamazaki H, Inoue K and Shimada T: Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 28: 103-115, 1998.